Tetanus and diphtheria toxoids adsorbed - Biologic Drug Details

Summary for tetanus and diphtheria toxoids adsorbed

Tradenames:	3
High Confidence Patents:	0
Applicants:	3
BLAs:	3
Suppliers: see list	4
Recent Clinical Trials:	See clinical trials for tetanus and diphtheria toxoids adsorbed

Recent Clinical Trials for tetanus and diphtheria toxoids adsorbed

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Servier	Phase 1
Katy Peters, MD, PhD	Phase 1
Gary Archer Ph.D.	Phase 2

See all tetanus and diphtheria toxoids adsorbed clinical trials

Pharmacology for tetanus and diphtheria toxoids adsorbed

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine
Chemical Structure	Diphtheria Toxoid Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tetanus and diphtheria toxoids adsorbed Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tetanus and diphtheria toxoids adsorbed Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for tetanus and diphtheria toxoids adsorbed Derived from Patent Text Search

No patents found based on company disclosures

Tetanus and Diphtheria Toxoids Adsorbed: Market Dynamics and Financial Trajectory

Introduction

The market for tetanus and diphtheria toxoids adsorbed, often combined with pertussis (DTP) vaccines, is a critical segment of the global vaccine industry. These vaccines are essential for preventing life-threatening diseases such as tetanus, diphtheria, and pertussis. Here, we delve into the market dynamics, financial trajectory, and key factors influencing this sector.

Market Size and Growth

The global diphtheria, pertussis, and tetanus (DTP) vaccine market has been experiencing steady growth. In 2019, the market was valued at $4,758.8 million and is projected to reach $7,054.4 million by 2027, with a Compound Annual Growth Rate (CAGR) of 5.1% during the forecast period[1].

Product Segmentation

The DTP vaccine market is segmented by product, with DTaP (diphtheria, tetanus, and acellular pertussis) vaccines holding the dominant position. DTaP vaccines are preferred due to their reduced side effects compared to whole-cell pertussis vaccines. This segment is expected to continue its lead over the forecast period[1].

Age Group Segmentation

The market is also segmented by age group, with pediatric vaccines being the most lucrative segment. The high demand for DTP vaccines among infants, driven by increasing birth rates and WHO norms requiring three doses of DTP vaccine for infants, contributes significantly to this segment's dominance. However, adult vaccines are expected to show high growth potential due to rising incidences of infectious diseases among adults[1].

Regional Analysis

Geographically, the DTP vaccine market is analyzed across North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa). North America dominated the market in 2019 and is anticipated to maintain this trend. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, driven by increasing demand, growing awareness of newer technologies, and a rising population[1].

End User Analysis

Hospitals hold the dominant position in the end-user segment and are expected to continue leading over the forecast period. This is due to the centralized nature of vaccine administration and the trust associated with hospital-based healthcare services[1].

Key Market Drivers

Several factors drive the growth of the DTP vaccine market:

• High Birth Rates: Increasing birth rates globally boost the demand for pediatric vaccines.
• Government Initiatives: Growth in initiatives taken by governments to enhance immunization programs and provide insurance and reimbursement scenarios.
• Research and Development: Advances in vaccine research and development, including the development of combination vaccines like tetravalent and pentavalent vaccines.
• Global Health Initiatives: Funding from organizations like GAVI (Global Alliance for Vaccines and Immunizations) supports the adoption of DTP-containing vaccines in underserved regions[1][4].

Financial Impact and Cost-Effectiveness

The economic evaluation of DTP vaccines highlights their cost-effectiveness. For instance, a study comparing DTaP and DTwP vaccines in the United States found that vaccination programs resulted in substantial savings from both societal and healthcare system perspectives. The benefit-cost ratios for DTaP were 27:1 and 9:1, respectively, indicating significant economic benefits[5].

Economic Evaluation of Tdap vs. Td

A study on replacing Td (tetanus and diphtheria toxoids) with Tdap (tetanus, diphtheria, and acellular pertussis) for decennial boosters showed that while Tdap is more expensive, it can lead to moderate decreases in pertussis cases and cost per Quality-Adjusted Life Year (QALY) saved, especially if pertussis incidence is higher than reported[2].

Technological Advancements

Technological breakthroughs, such as recombinant DNA technology, have improved the production and efficacy of toxoid vaccines. These advancements have led to the development of safer, more stable formulations with longer shelf lives, which are crucial for distribution in remote areas[4].

Combination Vaccines

The growing focus on combination vaccines, which include toxoid components, reduces the number of injections needed, thereby improving compliance and coverage rates. This trend is expected to continue, driving the market growth for DTP vaccines[4].

Regulatory and Market Forces

Regulatory and market forces play a significant role in the adoption of DTP vaccines. Public-private partnerships, such as those facilitated by GAVI, enhance vaccine accessibility in underserved regions. Governments implementing mandatory vaccination policies and campaigns also contribute to market growth[4].

Challenges and Restraints

Despite the growth, the market faces challenges such as:

• High Production Costs: Limited accessibility in low-income regions due to high production costs.
• Vaccine Hesitancy: Misinformation and hesitancy among some populations can hinder vaccine adoption[4].

Key Market Players

The DTP vaccine market is dominated by several key players, including Johnson & Johnson, Merck & Co., Inc., GlaxoSmithKline PLC (GSK), Sanofi, and Serum Institute of India Pvt. Ltd. These companies are driving market growth through enhanced vaccine R&D and strong product pipelines[1].

Conclusion

The market for tetanus and diphtheria toxoids adsorbed, particularly within the context of DTP vaccines, is poised for significant growth. Driven by increasing birth rates, government initiatives, and technological advancements, this market is expected to reach $7.054 billion by 2027. Despite challenges such as high production costs and vaccine hesitancy, the economic benefits and cost-effectiveness of these vaccines ensure their continued importance in global health strategies.

Key Takeaways

• The DTP vaccine market is projected to grow at a CAGR of 5.1% from 2019 to 2027.
• DTaP vaccines dominate the market and are expected to continue their lead.
• Pediatric vaccines are the most lucrative segment due to high demand among infants.
• Asia-Pacific is expected to witness the highest growth rate during the forecast period.
• Technological advancements and combination vaccines are key drivers of market growth.
• Regulatory and market forces, including public-private partnerships, enhance vaccine accessibility.

FAQs

What is the projected market size of the DTP vaccine market by 2027?

The DTP vaccine market is expected to reach $7,054.4 million by 2027[1].

Which segment dominates the DTP vaccine market?

The DTaP vaccine segment holds the dominant position in the DTP vaccine market[1].

What are the key drivers of the DTP vaccine market growth?

Key drivers include high birth rates, government initiatives, research and development, and global health initiatives[1][4].

How do technological advancements impact the DTP vaccine market?

Technological advancements, such as recombinant DNA technology, improve vaccine production and efficacy, leading to safer and more stable formulations[4].

What are the challenges faced by the DTP vaccine market?

Challenges include high production costs, limited accessibility in low-income regions, and vaccine hesitancy[4].

Sources

1. Allied Market Research - Diphtheria, Pertussis, and Tetanus (DTP) Vaccine Market
2. PubMed - Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
3. PubMed - Evidence That Regulatory And Market Forces Are Driving Adoption of Biosimilars
4. SNS Insider - Toxoid Vaccine Market Size, Share & Growth Analysis Report, 2032
5. PubMed - Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine (DTaP) or diphtheria and tetanus toxoids and whole-cell pertussis vaccine (DTwP)